Dr de Haan is Head of the Oxidative Stress Laboratory within the Diabetic Complications Division at the BakerIDI Heart and Diabetes Institute, Melbourne, Australia. Her interests lie in the pre-clinical assessment of novel antioxidant therapies to limit diabetic complications. Mimetics of the antioxidant enzyme, Glutathione peroxidase-1, have shown significant improvements in lessening diabetes-associated atherosclerosis (DAA) and diabetic nephropathy (DN). Her research has shown the potential of treating two diabetic complications with one monotherapy, an important finding given that these two diseases are often linked in diabetic patients. Other research interests include 1) the use of novel activators of the transcription factor, Nrf2, to bolster antioxidant defences to limit diabetic complications including DAA, DN and diabetic retinopathy; and 2) investigations of unique antagonist peptides to the Caveolin-1/eNOS interaction to limit endothelial dysfunction and DAA. Her in-depth understanding of how, when and where reactive oxygen species (ROS) contribute to these disease processes, and how to combat ROS through appropriate targeting, has been gained over more than 20 years of investigations into redox signalling and redox pathology.